DNA Encoded Library Market

DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    282

  • Pages
    278

  • View Count
    32639

Table Of Contents

1. PREFACE
1.1. DNA Encoded Library Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA Encoded Library Screening
3.3.4. Lead Generation
3.3.5. Lead Optimization

3.4. Overview of DNA Encoded Libraries
3.4.1. Encoding Strategies for Library Construction
3.4.2. Historical Evolution of DNA Encoded Libraries
3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
3.4.4. Key Advantages of DNA Encoded Libraries
3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries

3.5. Future Perspectives and Opportunity Areas

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Company / Organization
4.2.6. Analysis by Library Size
4.2.7. Analysis by Library Synthesis Method(s)
4.2.8. Analysis by Library Screening Method(s)
4.2.9. Analysis by Type of Product(s) Offered
4.2.10. Analysis by Type of Service(s) Offered
4.2.10.1. Analysis by Type of Library Design Service(s) Offered
4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
4.2.11. Analysis by Type of Pharmacological Lead(s)
4.2.12. Analysis by Therapeutic Target(s)
4.2.13. Analysis by Therapeutic Area(s)
4.2.14. Analysis by End-user(s)

5. BUSINESS MODEL ANALYSIS
5.1. Chapter Overview
5.2. DNA Encoded Library Companies: Business Model Analysis
5.2.1. Analysis by Operational Model
5.2.1.1. Analysis by Company Size and Operational Model
5.2.1.2. Analysis by Location of Headquarters and Operational Model
5.2.2. Analysis by Business Model
5.2.2.1. Analysis by Service Centric Model
5.2.2.2. Analysis by Product Centric Model
5.3. Concluding Remarks

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
6.4.1. DNA Encoded Library Companies based in North America
6.4.2. DNA Encoded Library Companies based in Europe
6.4.3. DNA Encoded Library Companies based in Asia-Pacific

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. AlphaMa
7.2.1. Company Overview
7.2.2. DNA Encoded Library Platform and Service Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. DICE Therapeutics
7.3.1. Company Overview
7.3.2. DNA Encoded Library Platform and Service Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. DyNAbind
7.4.1. Company Overview
7.4.2. DNA Encoded Library Platform and Service Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. HitGen
7.5.1. Company Overview
7.5.2. DNA Encoded Library Platform and Service Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. NovAliX
7.6.1. Company Overview
7.6.2. DNA Encoded Library Platform and Service Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Vipergen
7.7.1. Company Overview
7.7.2. DNA Encoded Library Platform and Service Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. WuXi AppTec
7.8.1. Company Overview
7.8.2. DNA Encoded Library Platform and Service Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. X-Chem
7.9.1. Company Overview
7.9.2. DNA Encoded Library Platform and Service Portfolio
7.9.3. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Encoded Libraries: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Type of Partner
8.3.6.1 Analysis by Partner Company Size
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. International and Local Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Encoded Libraries: Funding and Investment Analysis
9.3.1. Analysis of Instances by Year of Funding
9.3.2. Analysis of Amount Invested by Year of Funding
9.3.3. Analysis of Instances by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Most Active Players: Analysis by Amount Raised
9.3.7. Most Active Investors: Analysis by Number of Instances
9.3.8. Analysis by Geography
9.3.9. Concluding Remarks

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. DNA Encoded Libraries: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Type of Patent and Publication Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents

10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. DNA Encoded Libraries: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
11.4. Benchmark Analysis of Big Pharma Players
11.4.1. Spider Web Analysis: AbbVie
11.4.2. Spider Web Analysis: Amgen
11.4.3. Spider Web Analysis: AstraZeneca
11.4.4. Spider Web Analysis: Bayer
11.4.5. Spider Web Analysis: Boehringer Ingelheim
11.4.6. Spider Web Analysis: Eli Lilly
11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
11.4.8. Spider Web Analysis: Johnson & Johnson
11.4.9. Spider Web Analysis: Merck
11.4.10. Spider Web Analysis: Novartis
11.4.11. Spider Web Analysis: Pfizer
11.4.12. Spider Web Analysis: Sanofi
11.5. Concluding Remarks

12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES
12.1. Chapter Overview
12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters
12.2.4. Analysis by Company Size and Location of Headquarters
12.2.5. Analysis by Type of Company / Organization
12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035

13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035

13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035

13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035

13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035

13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035

13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Vipergen
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer

15.3. Serengen
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer

15.4. Deluge Biotechnologies
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President

15.5. NovAliX
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development

15.6. Orbit Discovery
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist

15.7. Anonymous

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Business Model Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Construction Process of a DNA Encoded Library
Figure 3.4 Encoding Strategies for Constructing DNA Encoded Libraries
Figure 3.5 Historical Evolution of DNA Encoded Libraries
Figure 3.6 Comparison of Traditional Libraries and DNA Encoded Libraries
Figure 3.7 Key Advantages of DNA Encoded Libraries
Figure 3.8 Challenges and Limitations Associated with DNA Encoded Libraries
Figure 4.1 DNA Encoded Libraries: Distribution by Year of Establishment
Figure 4.2 DNA Encoded Libraries: Distribution by Company Size
Figure 4.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
Figure 4.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
Figure 4.7 DNA Encoded Libraries: Distribution by Library Size
Figure 4.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
Figure 4.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
Figure 4.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
Figure 4.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
Figure 4.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
Figure 4.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
Figure 4.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
Figure 4.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
Figure 4.16 DNA Encoded Libraries: Distribution by End-user(s)
Figure 5.1 DNA Encoded Libraries: Distribution by Operational Model
Figure 5.2 DNA Encoded Libraries: Distribution by Company Size and Operational Model
Figure 5.3 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
Figure 5.4 DNA Encoded Libraries: Distribution by Business Model
Figure 5.5 DNA Encoded Libraries: Distribution by Service Centric Model
Figure 5.6 DNA Encoded Libraries: Distribution by Product Centric Model
Figure 6.1 Company Competitiveness Analysis: DNA Encoded Library Companies based in North America
Figure 6.2 Company Competitiveness Analysis: DNA Encoded Library Companies based in Europe
Figure 6.3 Company Competitiveness Analysis: DNA Encoded Library Companies based in Asia-Pacific
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
Figure 8.5 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8 Partnerships and Collaborations: Distribution by Partner Company Size
Figure 8.9 Most Active Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: International and Local Agreements
Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
Figure 9.2 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
Figure 9.3 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
Figure 9.4 Funding and Investment : Distribution of Instances by Type of Funding
Figure 9.5 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 9.8 Most Active Investors: Distribution by Number of Instances
Figure 9.9 Funding and Investment: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
Figure 9.10 Funding and Investment: Distribution of Number of Instances by Geography (Country-wise)
Figure 9.11 Funding and Investment: Summary of Investments by Number of Instances and Amount Invested (USD Million)
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
Figure 10.3 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
Figure 10.4 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Figure 10.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Figure 10.7 Patent Analysis: Distribution by CPC Symbols
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Patent Analysis: Distribution by Relative Patent Valuation
Figure 11.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharma Companies
Figure 11.2 Spider Web Analysis: AbbVie
Figure 11.3 Spider Web Analysis: Amgen
Figure 11.4 Spider Web Analysis: AstraZeneca
Figure 11.5 Spider Web Analysis: Bayer
Figure 11.6 Spider Web Analysis: Boehringer Ingelheim
Figure 11.7 Spider Web Analysis: Eli Lilly
Figure 11.8 Spider Web Analysis: GlaxoSmithKline (GSK)
Figure 11.9 Spider Web Analysis: Johnson & Johnson
Figure 11.10 Spider Web Analysis: Merck
Figure 11.11 Spider Web Analysis: Novartis
Figure 11.12 Spider Web Analysis: Pfizer
Figure 11.13 Spider Web Analysis: Sanofi
Figure 12.1 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
Figure 12.2 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
Figure 12.3 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
Figure 12.4 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
Figure 12.5 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
Figure 12.6 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
Figure 12.7 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035 (USD Billion)
Figure 13.4 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
Figure 13.5 DNA Encoded Library Market for Hit Generation / Identification, 2023-2035 (USD Million)
Figure 13.6 DNA Encoded Library Market for Hit to Lead, 2023-2035(USD Million)
Figure 13.7 DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035 (USD Million)
Figure 13.8 DNA Encoded Library Market for Other Application Areas, 2023-2035 (USD Million)
Figure 13.9 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 13.10 DNA Encoded Library Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 13.11 DNA Encoded Library Market for Immunological Disorders, 2023-2035 (USD Million)
Figure 13.12 DNA Encoded Library Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 13.13 DNA Encoded Library Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 13.14 DNA Encoded Library Market for Dermatological Disorders, 2023-2035 (USD Million)
Figure 13.15 DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 13.16 DNA Encoded Library Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 13.17 DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035 (USD Million)
Figure 13.18 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
Figure 13.19 DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035 (USD Million)
Figure 13.20 DNA Encoded Library Market for Academic / Research Institute, 2023-2035 (USD Million)
Figure 13.21 DNA Encoded Library Market for Other End-users, 2023-2035 (USD Million)
Figure 13.22 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
Figure 13.23 DNA Encoded Library Market: Upfront Payments, 2023-2035 (USD Million)
Figure 13.24 DNA Encoded Library Market: Milestone Payments, 2023-2035 (USD Million)
Figure 10.25 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 13.26 DNA Encoded Library Market in the US, 2023-2035 (USD Million)
Figure 13.27 DNA Encoded Library Market in Europe, 2023-2035 (USD Million)
Figure 13.28 DNA Encoded Library Market in Denmark, 2023-2035 (USD Million)
Figure 13.29 DNA Encoded Library Market in Germany, 2023-2035 (USD Million)
Figure 10.30 DNA Encoded Library Market in UK, 2023-2035 (USD Million)
Figure 13.31 DNA Encoded Library Market in Switzerland, 2023-2035 (USD Million)
Figure 13.32 DNA Encoded Library Market in France, 2023-2035 (USD Million)
Figure 13.33 DNA Encoded Library Market in Rest of the Europe, 2023-2035 (USD Million)
Figure 13.34 DNA Encoded Library Market in China, 2023-2035 (USD Million)
Figure 14.1 Concluding Remarks: Market Landscape
Figure 14.2 Concluding Remarks: Business Model Analysis
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Funding and Investment Analysis
Figure 14.5 Concluding Remarks: Patent Analysis
Figure 14.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 DNA Encoded Libraries: List of Service Providers / Platform Providers / In-House Companies
Table 4.2 DNA Encoded Libraries: Information on Library Size, Library Synthesis Method(s) and Library Screening Method(s)
Table 4.3 DNA Encoded Libraries: Information on Type of Product(s) and Service(s) Offered
Table 4.4 DNA Encoded Libraries: Information on Type of Pharmacological Lead(s) and Therapeutic Target(s)
Table 4.5 DNA Encoded Libraries: Information on Therapeutic Area(s) and End-user(s)
Table 5.1 DNA Encoded Libraries: Information on Company Size, Location of Headquarters and Operational Model
Table 5.2 DNA Encoded Libraries: Information on Business Model
Table 7.1 DNA Encoded Libraries: List of Companies Profiled
Table 7.2 AlphaMa: Company Snapshot
Table 7.3 AlphaMa: DNA Encoded Library Platform and Service Portfolio
Table 7.4 AlphaMa: Recent Developments and Future Outlook
Table 7.5 DICE Therapeutics: Company Snapshot
Table 7.6 DICE Therapeutics: DNA Encoded Library Platform and Service Portfolio
Table 7.7 DICE Therapeutics: Recent Developments and Future Outlook
Table 7.8 DyNAbind: Company Snapshot
Table 7.9 DyNAbind: DNA Encoded Library Platform and Service Portfolio
Table 7.10 DyNAbind: Recent Developments and Future Outlook
Table 7.11 HitGen: Company Snapshot
Table 7.12 HitGen: DNA Encoded Library Platform and Service Portfolio
Table 7.13 HitGen: Recent Developments and Future Outlook
Table 7.14 NovAliX: Company Snapshot
Table 7.15 NovAliX: DNA Encoded Library Platform and Service Portfolio
Table 7.16 NovAliX: Recent Developments and Future Outlook
Table 7.17 Vipergen: Company Snapshot
Table 7.18 Vipergen: DNA Encoded Library Platform and Service Portfolio
Table 7.19 Vipergen: Recent Developments and Future Outlook
Table 7.20 WuXi AppTec: Company Snapshot
Table 7.21 WuXi AppTec: DNA Encoded Library Platform and Service Portfolio
Table 7.22 X-Chem: Company Snapshot
Table 7.23 X-Chem: DNA Encoded Library Platform and Service Portfolio
Table 7.24 X-Chem: Recent Developments and Future Outlook
Table 8.1 DNA Encoded Libraries: List of Partnerships and Collaborations, 2010-2023
Table 9.1 DNA Encoded Libraries: List of Funding and Investments, 2018-2023
Table 10.1 Patent Analysis: Top CPC Sections
Table 10.2 Patent Analysis: Top CPC Symbols
Table 10.3 Patent Analysis: Top CPC Codes
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 12.1 DNA Encoded Libraries: List of Supporting Companies / Organizations
Table 12.2 DNA Encoded Libraries: Information on Type of Support Services / Ancillary Tools Offered
Table 13.1 DNA Encoded Libraries: Average Upfront Payment and Average Milestone Payment, 2016-2022 (USD Million)
Table 13.2 Library Licensing Deals: Tranches of Milestone Payments
Table 15.1 Vipergen: Company Key Highlights
Table 15.2 Serengen: Company Key Highlights
Table 15.3 Deluge Biotechnologies: Company Key Highlights
Table 15.4 NovAliX: Company Key Highlights
Table 15.5 Orbit Discovery: Company Key Highlights
Table 16.1 DNA Encoded Libraries: Distribution by Year of Establishment
Table 16.2 DNA Encoded Libraries: Distribution by Company Size
Table 16.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
Table 16.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
Table 16.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
Table 16.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
Table 16.7 DNA Encoded Libraries: Distribution by Library Size
Table 16.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
Table 16.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
Table 16.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
Table 16.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
Table 16.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
Table 16.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
Table 16.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
Table 16.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
Table 16.16 DNA Encoded Libraries: Distribution by End-user(s)
Table 16.17 DNA Encoded Libraries: Distribution by Operational Model
Table 16.18 DNA Encoded Libraries: Distribution by Company Size and Operational Model
Table 16.19 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
Table 16.20 DNA Encoded Libraries: Distribution by Business Model
Table 16.21 DNA Encoded Libraries: Distribution by Service Centric Model
Table 16.22 DNA Encoded Libraries: Distribution by Product Centric Model
Table 16.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
Table 16.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.26 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
Table 16.27 Partnerships and Collaborations: Distribution by Focus Area
Table 16.28 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.29 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.30 Partnerships and Collaborations: Distribution by Partner Company Size
Table 16.31 Most Active Players: Distribution by Number of Partnerships
Table 16.32 Partnerships and Collaborations: International and Local Agreements
Table 16.33 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.34 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
Table 16.35 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
Table 16.36 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
Table 16.37 Funding and Investment: Distribution of Instances by Type of Funding
Table 16.38 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
Table 16.39 Most Active Players: Distribution by Number of Funding Instances
Table 16.40 Most Active Players: Distribution by Amount Raised (USD Million)
Table 16.41 Most Active Investors: Distribution by Number of Instances
Table 16.42 Funding and Investment Analysis: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
Table 16.43 Funding and Investment Analysis: Distribution of Number of Instances by Geography (Country-wise)
Table 16.44 Funding and Investment Analysis: Summary of Investments by Number of Instances and Amount Invested (USD Million)
Table 16.45 Patent Analysis: Distribution by Type of Patent
Table 16.46 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
Table 16.47 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
Table 16.48 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
Table 16.49 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Table 16.50 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Table 16.51 Patent Analysis: Distribution by CPC Symbols
Table 16.52 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.53 Leading Industry Players: Distribution by Number of Patents
Table 16.54 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.55 Leading Individual Assignees: Distribution by Number of Patents
Table 16.56 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 16.57 Patent Analysis: Distribution by Patent Age
Table 16.58 Patent Analysis: Distribution by Relative Patent Valuation
Table 16.59 Big Pharma Players: Heat Map Analysis of Top Pharma Companies
Table 16.60 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
Table 16.61 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
Table 16.62 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
Table 16.63 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
Table 16.64 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
Table 16.65 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
Table 16.66 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
Table 16.67 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Opportunity, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
Table 16.68 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
Table 16.69 DNA Encoded Library Market for Hit Generation / Identification, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.70 DNA Encoded Library Market for Hit to Lead, Conservative, Base and Optimistic Scenarios, 2023-2035(USD Million)
Table 16.71 DNA Encoded Library Market for Hit Validation / Optimization, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.72 DNA Encoded Library Market for Other Application Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.73 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Table 16.74 DNA Encoded Library Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.75 DNA Encoded Library Market for Immunological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.76 DNA Encoded Library Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.77 DNA Encoded Library Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.78 DNA Encoded Library Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.79 DNA Encoded Library Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.80 DNA Encoded Library Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.81 DNA Encoded Library Market for Other Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.82 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
Table 16.83 DNA Encoded Library Market for Pharma / Biopharma Industry, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.84 DNA Encoded Library Market for Academic / Research Institute, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.85 DNA Encoded Library Market for Other End-users, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.86 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
Table 16.87 DNA Encoded Library Market: Upfront Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.88 DNA Encoded Library Market: Milestone Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.89 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 16.90 DNA Encoded Library Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.91 DNA Encoded Library Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.92 DNA Encoded Library Market in Denmark, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.93 DNA Encoded Library Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.94 DNA Encoded Library Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.95 DNA Encoded Library Market in Switzerland, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.96 DNA Encoded Library Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.97 DNA Encoded Library Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.98 DNA Encoded Library Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 1859, Inc.
  2. 6 Dimensions Capital
  3. AbbVie
  4. Abilita Bio
  5. Actelion Pharmaceuticals
  6. Aduro Biotech
  7. Agent Capital
  8. Air Street Capital
  9. Alex’s Lemonade Stand Foundation
  10. Alexandria Venture Investments
  11. Alexion
  12. Aligos Therapeutics
  13. ALK
  14. Alkermes
  15. Almac Discovery
  16. Almirall
  17. AlphaMa
  18. Altitude Life Science Ventures
  19. Amadeus Capital Partners
  20. Amgen
  21. Anagenex
  22. Anavo Therapeutics
  23. Andreessen Horowitz
  24. Animol Discovery
  25. Anterra Capital
  26. Arbutus Biopharma
  27. ARCH Venture Partners
  28. Arclight
  29. Arvinas
  30. ASINEX
  31. Astellas Pharma
  32. Astellas Venture Management
  33. AstraZeneca
  34. Asymmetry Capital Management
  35. Atlas Venture
  36. AviSyn Pharma (acquired by X-Chem)
  37. Azenta Life Sciences
  38. Bain Capital Life Sciences
  39. BASF
  40. Bayer
  41. Baylor College of Medicine
  42. BGF
  43. BigRio
  44. Bill & Melinda Gates Foundation
  45. BioAge Labs
  46. BioDuro-Sundia
  47. Biogen
  48. BIONET
  49. BOC Sciences
  50. Boehringer Ingelheim
  51. Borealis Ventures
  52. Boxer Capital
  53. Bpifrance
  54. Bridge Biotherapeutics
  55. Bristol Myers Squibb
  56. BVF Partners
  57. C4X Discovery
  58. Cambridge Enterprise
  59. Cambridge Molecular
  60. Canada Pension Plan Investment Board
  61. Cancer Research Technology
  62. Cancer Research UK
  63. Carterra
  64. Casdin Capital
  65. Casma Therapeutics
  66. Catalio Capital Management
  67. CDH Investments
  68. Cedilla Therapeutics
  69. Central European Institute of Technology
  70. Charles River
  71. Charles River Ventures
  72. ChemDiv
  73. ChemRoutes
  74. Chemspace
  75. Citadel Discovery
  76. Cocrystal Pharma
  77. Columbia University
  78. ComInnex (acquired by X-Chem)
  79. Confo Therapeutics
  80. Crelux
  81. Cyclofluidic
  82. D. E. Shaw
  83. Daewoong Pharmaceutical
  84. Daiichi Sankyo
  85. DCVC Bio
  86. Deep Track Capital
  87. Deluge Biotechnologies
  88. DICE Therapeutics
  89. Domainex
  90. Dorian Therapeutics
  91. Dresden University of Technology (TUD)
  92. Driehaus Capital Management
  93. Duke University
  94. DyNAbind
  95. EcoR1 Capital
  96. Edelris
  97. Eli Lilly
  98. Enamine
  99. Encodia
  100. Endevica Bio
  101. Enko
  102. EQRx
  103. ETH Zurich
  104. European Regional Development Fund (ERDF)
  105. Eventide Asset Management
  106. Evotec
  107. Exo Therapeutics
  108. Finistere Ventures
  109. Fisher Scientific
  110. Foresite Capital
  111. Forma Therapeutics
  112. Franzini Research
  113. Galapagos
  114. Genentech
  115. GenScript
  116. GHO Capital
  117. Gilead Sciences
  118. Glamorous AI (acquired by X-Chem)
  119. GlaxoSmithKline (GSK)
  120. Global Blood Therapeutics
  121. Google
  122. Google Ventures
  123. Harvard College
  124. Haystack Sciences (acquired by insitro)
  125. Heptares Therapeutics
  126. High-Tech Gründerfonds (HTGF)
  127. HitGen
  128. Hope City Church
  129. HotSpot Therapeutics
  130. Howard Hughes Medical Institute
  131. Innovate UK
  132. Inscripta
  133. insitro
  134. IntelliSyn (acquired by X-Chem)
  135. InterX (acquired by NeoTX)
  136. Janssen
  137. Janus Henderson Investors
  138. Johnson & Johnson
  139. Kaken Pharmaceutical
  140. Khosla Ventures
  141. Kymera Therapeutics
  142. Leadyond Capital
  143. LEO Pharma
  144. LG Chem
  145. LGC Biosearch Technologies
  146. Life Chemicals
  147. Lipigon
  148. Liverpool ChiroChem
  149. Logos Capital
  150. LoQus23 Therapeutics
  151. Lux Capital
  152. M Ventures
  153. Macroceutics (acquired by HotSpot Therapeutics)
  154. Maruho
  155. Max Planck Institute of Molecular Physiology (MPI)
  156. Mcule
  157. MD Anderson Cancer Center
  158. MedChemExpress (MCE)
  159. Menlo Ventures
  160. Merck
  161. Mitsubishi Tanabe Pharma
  162. MolPort
  163. Morningside Ventures
  164. Morphic Therapeutic
  165. Namiki Shoji
  166. Navitor Pharmaceuticals
  167. Neotribe Ventures
  168. NetVation DL Medicine
  169. New Leaf Venture Partners
  170. Newpath Partners
  171. Nextech Invest
  172. Nitrase Therapeutics
  173. Northpond Ventures
  174. Northwestern University
  175. Novalis LifeSciences
  176. NovAliX
  177. Novartis
  178. Novartis Venture Fund
  179. Nuevolution (acquired by Amgen)
  180. Nurix Therapeutics
  181. O2h Ventures
  182. Obvious Ventures
  183. OMass Therapeutics
  184. Oncodesign
  185. Ono Pharmaceutical
  186. Orbit Discovery
  187. Orexia
  188. Osage University Partners
  189. Otsuka Pharmaceutical
  190. Oxford Sciences Innovation
  191. Oxford University
  192. PACS1 Syndrome Research Foundation
  193. Pappas Capital
  194. Parkwalk Advisors
  195. Perceptive Advisors
  196. Perivoli Innovations
  197. Pfizer
  198. PharmaBlock Sciences
  199. Pharmacelera
  200. Pharmaceutical Product Development (PPD)
  201. Pharmaron
  202. PharmStars
  203. Philochem
  204. Philogen
  205. PhoreMost
  206. PhyNexus (acquired by Biotage)
  207. Pioneering Medicines
  208. Pivotal bioVenture Partners
  209. Plexium
  210. Praecis Pharmaceuticals (acquired by GSK )
  211. Princeton University
  212. Proteros Biostructures
  213. PROvendis
  214. PsyBrain
  215. Pulsar Bio
  216. RA Capital Management
  217. Receptor.AI
  218. Recludix Pharma
  219. Redmile Group
  220. Relay Therapeutics
  221. Roche
  222. Roivant Sciences
  223. RT Ventures
  224. S.R. One
  225. Sahsen Ventures
  226. Salipro Biotech
  227. Samsara BioCapital
  228. Sands Capital
  229. SanegeneBio
  230. Sanofi
  231. Sanofi Ventures
  232. SciLifeLab
  233. Scilligence
  234. Serengen
  235. Servier
  236. Signel IX
  237. Simcere Pharmaceutical
  238. Sironax
  239. Sofinnova Partners
  240. SoftBank Vision Fund
  241. Soleus Capital
  242. SpiroChem
  243. Sun Pharma Advanced Research Company (SPARC)
  244. Surveyor Capital (a Citadel company)
  245. Symeres
  246. SyntheX
  247. Taiho Pharmaceutical
  248. Takeda
  249. Tasly Pharmaceuticals
  250. Tavistock Group
  251. TCG Crossover (TCG X)
  252. Technical University of Dortmund
  253. Technology Founder Fund Saxony (TGFS )
  254. Temasek
  255. The California Institute for Biomedical Research (Calibr)
  256. The Column Group (TCG)
  257. The Scripps Research Institute
  258. Theseus Pharmaceuticals
  259. Third Rock Ventures
  260. Trend Investment Group
  261. Trilo Therapeutics
  262. TUDAG
  263. Two Sigma Ventures
  264. UNC Drug Discovery Initiative
  265. University of Edinburgh
  266. University of Manchester
  267. University of Pennsylvania
  268. UPPthera
  269. Valo Health
  270. Veritas In Silico
  271. Vernalis Research (acquired by HitGen)
  272. Vertex Pharmaceuticals
  273. Vipergen
  274. Viva Biotech
  275. Wake Forest University
  276. Warp Drive Bio
  277. Wellington Management Company
  278. WuXi AppTec
  279. X-Chem
  280. XtalPi
  281. Zai Lab
  282. ZebiAI (acquired by Relay Therapeutics)

Source 1: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/how-clinical-trials-are-planned-and-organised/how-long-it-takes-for-a-new-drug-to-go-through-clinical-trials
Source 2: https://www.prnewswire.com/news-releases/enko-advances-enkompass-platform-through-dna-encoded-library-technology-enablement-from-x-chem-301567231.html

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com